^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    AE 37

    i
    Associations
    News

    Trials

    Company:
    Generex, Shenzhen BioScien
    Drug class:
    Immunostimulant
    Related drugs:
    Associations
    News

    Trials

    Apply
    Establishing the Recommended Biological Dose for AE37 Peptide Vaccine in Combination With Pembrolizumab That Will Enhance the Tumor-specific Immune Response and Demonstrate Efficacy in Patients With Advanced Triple-negative Breast Cancer (NSABP FB-14) (NCT04024800)
    Phase 2
    NuGenerex Immuno-Oncology
    Active, not recruiting
    Last update posted :
    06/02/2021
    Initiation :
    05/03/2019
    Primary completion :
    06/30/2023
    Completion :
    06/30/2024
    HER-2
    |
    HER-2 negative
    |
    Keytruda (pembrolizumab) • AE 37
    Vaccine Therapy in Treating Patients With Breast Cancer (BAMC-C.2007.098) (NCT00524277)
    Phase 2
    San Antonio Military Medical Center
    Completed
    Last update posted :
    03/30/2020
    Initiation :
    01/01/2007
    Primary completion :
    12/31/2014
    Completion :
    03/31/2017
    HER-2 • ER • PGR • CSF2
    |
    HER-2 amplification • HER-2 expression • HLA-A2 positive • PGR negative
    |
    AE 37 • GLSI-100 • Leukine (sargramostim)